Quarterly ResultMay 12, 2026, 04:19 PM
Maze Therapeutics Q1 Net Loss Narrows to $24.2M; Secures $40M Loan
AI Summary
Maze Therapeutics reported a net loss of $24.2 million for Q1 2026, a reduction from $32.8 million in Q1 2025, driven by $20.0 million in license revenue. The company secured an initial $40.0 million term loan from a new $200.0 million facility in February 2026. Additionally, subsequent to the quarter end, Maze Therapeutics completed a $144.7 million equity offering and received a $20.0 million milestone payment, which are expected to fund operations for at least one year.
Key Highlights
- Q1 2026 net loss narrowed to $24.2 million from $32.8 million in Q1 2025.
- Recognized $20.0 million in license revenue for Q1 2026, up from $0 in Q1 2025.
- Research and development expenses increased to $34.1 million from $27.6 million year-over-year.
- General and administrative expenses rose to $12.4 million from $7.8 million year-over-year.
- Secured an initial $40.0 million term loan from a new $200.0 million facility in February 2026.
- Completed a $144.7 million equity offering and received a $20.0 million milestone payment in April 2026.
- Cash, cash equivalents, and marketable securities totaled $362.9 million as of March 31, 2026.
Price Impact
More from MAZE